Top Markets
Coin of the day
Immage Biotherapeutics Corp. Immage Biotherapeutics Corp.

Immage Biotherapeutics Corp.

IMMG
Rank in Stocks #41597
Presently, Immage Biotherapeutics Corp. lacks substantial business operations.... Presently, Immage Biotherapeutics Corp. lacks substantial business operations. Historically, its endeavors centered on the creation of cutting-edge immunotherapy biologics designed to combat diverse cancer types across the United States. Established in 2012, the entity was initially known as Epicure Charcoal, Inc., rebranding to Immage Biotherapeutics Corp. in June 2015. Its corporate headquarters are situated in Bethesda, Maryland, and it operates as a subsidiary of Coventry International Limited.
Share Price
$0.0001
Last synced: 2026-08-11
Market Cap
$15.17K
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Immage Biotherapeutics Corp. (IMMG)
P/E ratio for Immage Biotherapeutics Corp. (IMMG)
P/E ratio as of 2026 TTM: 0
According to Immage Biotherapeutics Corp. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Immage Biotherapeutics Corp. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.